Dantrolene: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 55: | Line 55: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:57, 20 March 2026
Administration
- Type: Skeletal muscle relaxant
- Dosage Forms:
- Routes of Administration: IV, oral
- Common Trade Names: Dantrium
Adult Dosing
Neuroleptic malignant syndrome
- 0.25-2mg/kg IV q6-12hr
- Max dose 10mg/kg/day
Pediatric Dosing
- Same as above
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: contraindicated in acute hepatitis or active cirrhosis
Contraindications
- Allergy to class/drug
- Acute hepatitis or active cirrhosis
Adverse Reactions
Serious
- Hepatotoxicity
- GI bleed
- Aplastic anemia, leukopenia, thrombocytopenia, small lymphocytic lymphoma
- Muscle weakness, dysphagia, reduced vital capacity, dyspnea
Common
- Flushing
- Somnolence, fatigue, malaise
- Nausea, diarrhea
Pharmacology
- Half-life: 10.8h
- Metabolism: Hepatic
- Excretion:
Mechanism of Action
- Interferes with release of calcium ions from sarcoplasmic reticulum in skeletal muscle, which results in dissociation of the excitation-contraction coupling
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.